Today: Today, 13,650 Shares of Stock are sold by Insider Selling: Edwards Lifesciences Corp. (EW) VP

Today, 13,650 Shares of Stock are sold by Insider Selling: Edwards Lifesciences Corp. (EW) VP

Edwards Lifesciences Corp. (NYSE:EW) VP Huimin Wang sold 13,650 shares of the stock in a transaction that occurred on Wednesday, October 5th. The stock was sold at an average price of $120.04, for a total transaction of $1,638,546.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Huimin Wang also recently made the following trade(s): On Tuesday, September 6th, Huimin Wang sold 13,650 shares of Edwards Lifesciences Corp. stock. The shares were sold at an average price of $115.72, for a total transaction of $1,579,578.00. On Friday, August 5th, Huimin Wang sold 13,650 shares of Edwards Lifesciences Corp. stock. The shares were sold at an average price of $113.03, for a total transaction of $1,542,859.50.

Shares of Edwards Lifesciences Corp. (NYSE:EW) opened at 119.72 on Friday. Edwards Lifesciences Corp. has a 52 week low of $71.93 and a 52 week high of $121.73. The company has a market capitalization of $25.49 billion, a price-to-earnings ratio of 49.47 and a beta of 0.56. The stock has a 50 day moving average of $117.36 and a 200-day moving average of $106.97.

10/07/insider-selling-edwards-lifesciences-corp-ew-vp-sells-13650-shares-of-stock.html

Edwards Lifesciences Corp. (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 26th. The medical research company reported $0.76 EPS for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.06. The firm had revenue of $759.30 million for the quarter, compared to analysts’ expectations of $724.26 million. Edwards Lifesciences Corp. had a net margin of 19.26% and a return on equity of 23.72%. The business’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.57 earnings per share. On average, analysts anticipate that Edwards Lifesciences Corp. will post $2.88 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of EW. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Edwards Lifesciences Corp. during the second quarter worth approximately $100,000. Quadrant Capital Group LLC boosted its position in shares of Edwards Lifesciences Corp. by 2.3% in the second quarter. Quadrant Capital Group LLC now owns 1,108 shares of the medical research company’s stock valued at $106,000 after buying an additional 25 shares during the last quarter. Exane Derivatives acquired a new position in shares of Edwards Lifesciences Corp. during the second quarter valued at about $118,000. Duncker Streett & Co. Inc. boosted its position in shares of Edwards Lifesciences Corp. by 10.5% in the second quarter. Duncker Streett & Co. Inc. now owns 1,264 shares of the medical research company’s stock valued at $126,000 after buying an additional 120 shares during the last quarter. Finally, Oakworth Capital Inc. acquired a new position in shares of Edwards Lifesciences Corp. during the second quarter valued at about $126,000. Hedge funds and other institutional investors own 84.09% of the company’s stock.

Several analysts have recently weighed in on EW shares. Wells Fargo & Co. restated a “buy” rating on shares of Edwards Lifesciences Corp. in a research report on Sunday, September 11th. Evercore ISI restated a “hold” rating and set a $115.00 price objective on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. Leerink Swann restated a “buy” rating on shares of Edwards Lifesciences Corp. in a research report on Friday, August 19th. Piper Jaffray Cos. restated an “overweight” rating and set a $123.00 price objective on shares of Edwards Lifesciences Corp. in a research report on Tuesday, June 21st. Finally, Barclays PLC raised their price objective on shares of Edwards Lifesciences Corp. from $105.00 to $115.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company’s stock. Edwards Lifesciences Corp. has a consensus rating of “Buy” and an average price target of $118.13.

Edwards Lifesciences Corp. Company Profile

Related posts

Leave a Comment